TNFRSF8 and Hodgkins lymphoma: Brentuximab vedotin received conditional approval from the European Medicines Agency for the treatment of adult patients with relapsed/refractory (R/R) CD30-positive HL following ASCT or ≥2 prior multiagent chemotherapy regimens when ASCT or multiagent chemotherapy is not a treatment option, as consolidation for CD30-positive HL patients at increased risk of relapse or progression following ASCT, and for the treatment of R/R sALCL [33].